Multiregion whole-exome sequencing uncovers the genetic evolution and mutational heterogeneity of early-stage metastatic melanoma

Cancer Research

Volumn 76, Issue 16, 2016, Pages 4765-4774

  Harbst, Katja ^a   Lauss, Martin ^a   Cirenajwis, Helena ^a   Isaksson, Karolin ^b   Rosengren, Frida ^a   Törngren, Therese ^a   Kvist, Anders ^a   Johansson, Maria C ^a   Vallon Christersson, Johan ^a   Baldetorp, Bo ^a   Borg, Åke ^a   Olsson, Håkan ^a,b   Ingvar, Christian ^a,b   Carneiro, Ana ^a,b   Jönsson, Göran ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; CYTOSINE; DACARBAZINE; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; TEMOZOLOMIDE; THYMINE; TRANSCRIPTOME;

ALLELE; ARTICLE; BRAF GENE; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CARCINOGENESIS; CLINICAL ARTICLE; DNA SEQUENCE; EXOME; GENETIC HETEROGENEITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; METASTATIC MELANOMA; MOLECULAR EVOLUTION; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; NUCLEIC ACID BASE SUBSTITUTION; ONCOGENE N RAS; PRIORITY JOURNAL; RNA SEQUENCE; SOMATIC MUTATION; TUMOR BIOPSY; ULTRAVIOLET B RADIATION; DNA MUTATIONAL ANALYSIS; GENETICS; MELANOMA; MUTATION; PROCEDURES;

DNA MUTATIONAL ANALYSIS; EVOLUTION, MOLECULAR; EXOME; HUMANS; MELANOMA; MUTATION; TRANSCRIPTOME;

EID: 84982179452     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-3476     Document Type: Article

References (33)

1. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.
2. Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 2014;46:225-33.
3. De Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 2014;346:251-6.
4. Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 2014;346:256-9.
5. Bashashati A, Ha G, Tone A, Ding J, Prentice LM, Roth A, et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol 2013;231:21-34.
6. Boutros PC, Fraser M, Harding NJ, De Borja R, Trudel D, Lalonde E, et al. Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat Genet 2015;47:736-45.
7. Cooper CS, Eeles R, Wedge DC, Van Loo P, Gundem G, Alexandrov LB, et al. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat Genet 2015;47:367-72.
8. Murugaesu N, Wilson GA, Birkbak NJ, Watkins TB, McGranahan N, Kumar S, et al. Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy. Cancer Discov 2015;5:821-31.
9. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature 2013;500:415-21.
10. Harbst K, Lauss M, Cirenajwis H, Winter C, Howlin J, Torngren T, et al. Molecular and genetic diversity in the metastatic process of melanoma. J Pathol 2014;233:39-50.
11. Sanborn JZ, Chung J, Purdom E, Wang NJ, Kakavand H, Wilmott JS, et al. Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. Proc Natl Acad Sci U S A 2015;112:10995-1000.
12. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
13. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013;152:714-26.
14. Mroz EA, Rocco JW. MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma. Oral Oncol 2013;49:211-5.
15. Kemper K, Krijgsman O, Cornelissen-Steijger P, Shahrabi A, Weeber F, Song JY, et al. Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts. EMBO Mol Med 2015;7:1104-18.
16. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 2013;31:213-9.
17. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 2012;22:568-76.
18. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010;38:e164.
19. Li J, Lupat R, Amarasinghe KC, Thompson ER, Doyle MA, Ryland GL, et al. CONTRA: copy number analysis for targeted resequencing. Bioinformatics 2012;28:1307-13.
20. Hupe P, Stransky N, Thiery JP, Radvanyi F, Barillot E. Analysis of arrayCGH data: from signal ratio to gain and loss of DNA regions. Bioinformatics 2004;20:3413-22.
21. Carter SL, Cibulskis K, Helman E, McKenna A, Shen H, Zack T, et al. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol 2012;30:413-21.
22. Cirenajwis H, Ekedahl H, Lauss M, Harbst K, Carneiro A, Enoksson J, et al. Molecular stratification of metastatic melanoma using gene expression profiling: Prediction of survival outcome and benefit from molecular targeted therapy. Oncotarget 2015;6:12297-309.
23. Saal LH, Vallon-Christersson J, Hakkinen J, Hegardt C, Grabau D, Winter C, et al. The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine. Genome Med 2015;7:20.
24. The Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 2015;161:1681-96.
25. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24:4340-6.
26. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, et al. A census of human cancer genes. Nat Rev Cancer 2004;4:177-83.
27. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005;65:2554-9.
28. Drobetsky EA, Turcotte J, Chateauneuf A. A role for ultraviolet A in solar mutagenesis. Proc Natl Acad Sci U S A 1995;92:2350-4.
29. Castle JC, Loewer M, Boegel S, Tadmor AD, Boisguerin V, De Graaf J, et al. Mutated tumor alleles are expressed according to their DNA frequency. Sci Rep 2014;4:4743.
30. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, et al. A landscape of driver mutations in melanoma. Cell 2012;150:251-63.
31. Haarberg HE, Smalley KS. Resistance to Raf inhibition in cancer. Drug Discov Today Technol 2014;11:27-32.
32. Mengelbier LH, Karlsson J, Lindgren D, Valind A, Lilljebjorn H, Jansson C, et al. Intratumoral genome diversity parallels progression and predicts outcome in pediatric cancer. Nat Commun 2015;6:6125.
33. Shain AH, Yeh I, Kovalyshyn I, Sriharan A, Talevich E, Gagnon A, et al. The genetic evolution of melanoma from precursor lesions. N Engl J Med 2015;373:1926-36.